ZA200402530B - Use of histamine to treat liver disease. - Google Patents
Use of histamine to treat liver disease. Download PDFInfo
- Publication number
- ZA200402530B ZA200402530B ZA200402530A ZA200402530A ZA200402530B ZA 200402530 B ZA200402530 B ZA 200402530B ZA 200402530 A ZA200402530 A ZA 200402530A ZA 200402530 A ZA200402530 A ZA 200402530A ZA 200402530 B ZA200402530 B ZA 200402530B
- Authority
- ZA
- South Africa
- Prior art keywords
- ros
- group
- liver
- histamine
- release
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title claims description 138
- 229960001340 histamine Drugs 0.000 title claims description 69
- 208000019423 liver disease Diseases 0.000 title claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 151
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 141
- 239000003814 drug Substances 0.000 claims description 59
- 210000004185 liver Anatomy 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 54
- 238000004519 manufacturing process Methods 0.000 claims description 50
- 231100000334 hepatotoxic Toxicity 0.000 claims description 34
- 230000003082 hepatotoxic effect Effects 0.000 claims description 34
- 239000002516 radical scavenger Substances 0.000 claims description 32
- 230000006378 damage Effects 0.000 claims description 30
- -1 nitrofuratoin Chemical compound 0.000 claims description 26
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 22
- 208000006454 hepatitis Diseases 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 19
- 210000003494 hepatocyte Anatomy 0.000 claims description 16
- 108060006004 Ascorbate peroxidase Proteins 0.000 claims description 15
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 15
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 15
- 235000005865 Symphytum officinale Nutrition 0.000 claims description 15
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 230000002440 hepatic effect Effects 0.000 claims description 14
- 231100000283 hepatitis Toxicity 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 13
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 12
- 208000004930 Fatty Liver Diseases 0.000 claims description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 12
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 12
- 229940044601 receptor agonist Drugs 0.000 claims description 12
- 239000000018 receptor agonist Substances 0.000 claims description 12
- 102000016938 Catalase Human genes 0.000 claims description 11
- 108010053835 Catalase Proteins 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 11
- 102000000543 Histamine Receptors Human genes 0.000 claims description 11
- 108010002059 Histamine Receptors Proteins 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 229940076279 serotonin Drugs 0.000 claims description 11
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 244000126014 Valeriana officinalis Species 0.000 claims description 10
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 10
- 230000007882 cirrhosis Effects 0.000 claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 10
- 230000000451 tissue damage Effects 0.000 claims description 10
- 235000016788 valerian Nutrition 0.000 claims description 10
- 102000004722 NADPH Oxidases Human genes 0.000 claims description 9
- 108010002998 NADPH Oxidases Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 208000007232 portal hypertension Diseases 0.000 claims description 9
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 8
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 8
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 8
- 240000002299 Symphytum officinale Species 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 208000010706 fatty liver disease Diseases 0.000 claims description 8
- 229960003350 isoniazid Drugs 0.000 claims description 8
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 8
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 7
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 7
- 229960005489 paracetamol Drugs 0.000 claims description 7
- 229960002036 phenytoin Drugs 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 239000003263 anabolic agent Substances 0.000 claims description 6
- 239000003862 glucocorticoid Substances 0.000 claims description 6
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 6
- 230000007686 hepatotoxicity Effects 0.000 claims description 6
- 230000004792 oxidative damage Effects 0.000 claims description 6
- 229960002695 phenobarbital Drugs 0.000 claims description 6
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 6
- 229960002393 primidone Drugs 0.000 claims description 6
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 6
- 231100000827 tissue damage Toxicity 0.000 claims description 6
- 229940045997 vitamin a Drugs 0.000 claims description 6
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 5
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 5
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 5
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 244000025596 Cassia laevigata Species 0.000 claims description 5
- 235000006693 Cassia laevigata Nutrition 0.000 claims description 5
- 229930186147 Cephalosporin Natural products 0.000 claims description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 5
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 5
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 5
- 241001219085 Cyclopia Species 0.000 claims description 5
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 5
- 235000014066 European mistletoe Nutrition 0.000 claims description 5
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 claims description 5
- 244000073231 Larrea tridentata Species 0.000 claims description 5
- 235000006173 Larrea tridentata Nutrition 0.000 claims description 5
- 201000004602 Peliosis Hepatis Diseases 0.000 claims description 5
- 229930182555 Penicillin Natural products 0.000 claims description 5
- 244000152640 Rhipsalis cassutha Species 0.000 claims description 5
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims description 5
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 241001072888 Teucrium Species 0.000 claims description 5
- 241000519996 Teucrium chamaedrys Species 0.000 claims description 5
- 241000221012 Viscum Species 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 5
- 229960003459 allopurinol Drugs 0.000 claims description 5
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 5
- 229960005260 amiodarone Drugs 0.000 claims description 5
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 5
- 229960003022 amoxicillin Drugs 0.000 claims description 5
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 5
- 229960002170 azathioprine Drugs 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
- 229960000830 captopril Drugs 0.000 claims description 5
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 5
- 229940124587 cephalosporin Drugs 0.000 claims description 5
- 150000001780 cephalosporins Chemical class 0.000 claims description 5
- 229960001076 chlorpromazine Drugs 0.000 claims description 5
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 5
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 5
- 229960001214 clofibrate Drugs 0.000 claims description 5
- 229940047766 co-trimoxazole Drugs 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229960001259 diclofenac Drugs 0.000 claims description 5
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 5
- 229960002656 didanosine Drugs 0.000 claims description 5
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 5
- 229960004166 diltiazem Drugs 0.000 claims description 5
- 229960003276 erythromycin Drugs 0.000 claims description 5
- 229960005309 estradiol Drugs 0.000 claims description 5
- 229930182833 estradiol Natural products 0.000 claims description 5
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 5
- 229960002001 ethionamide Drugs 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 229960004273 floxacillin Drugs 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 5
- 229960003132 halothane Drugs 0.000 claims description 5
- 201000011200 hepatorenal syndrome Diseases 0.000 claims description 5
- 229960001680 ibuprofen Drugs 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 229960003284 iron Drugs 0.000 claims description 5
- 229960002725 isoflurane Drugs 0.000 claims description 5
- 239000008500 jin bu huan Substances 0.000 claims description 5
- 229940107491 kava root Drugs 0.000 claims description 5
- 229960004125 ketoconazole Drugs 0.000 claims description 5
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 5
- 229960000681 leflunomide Drugs 0.000 claims description 5
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000002960 penicillins Chemical class 0.000 claims description 5
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004448 pentamidine Drugs 0.000 claims description 5
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims description 5
- 229960000244 procainamide Drugs 0.000 claims description 5
- 229960005206 pyrazinamide Drugs 0.000 claims description 5
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 5
- 229960001404 quinidine Drugs 0.000 claims description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 5
- 229960001225 rifampicin Drugs 0.000 claims description 5
- 229940124513 senna glycoside Drugs 0.000 claims description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 5
- 150000003456 sulfonamides Chemical class 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 229960003991 trazodone Drugs 0.000 claims description 5
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims description 5
- 229960000497 trovafloxacin Drugs 0.000 claims description 5
- 229960000604 valproic acid Drugs 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 5
- 229960002555 zidovudine Drugs 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 4
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 4
- 241000218671 Ephedra Species 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 208000027472 Galactosemias Diseases 0.000 claims description 4
- 208000009139 Gilbert Disease Diseases 0.000 claims description 4
- 208000022412 Gilbert syndrome Diseases 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 206010018464 Glycogen storage disease type I Diseases 0.000 claims description 4
- 208000018565 Hemochromatosis Diseases 0.000 claims description 4
- 208000003591 Hepatoerythropoietic Porphyria Diseases 0.000 claims description 4
- 206010019842 Hepatomegaly Diseases 0.000 claims description 4
- 206010024652 Liver abscess Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 201000007981 Reye syndrome Diseases 0.000 claims description 4
- 241000519989 Scutellaria galericulata Species 0.000 claims description 4
- 208000018839 Wilson disease Diseases 0.000 claims description 4
- 201000004525 Zellweger Syndrome Diseases 0.000 claims description 4
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims description 4
- 201000010275 acute porphyria Diseases 0.000 claims description 4
- 229940070021 anabolic steroids Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 201000005271 biliary atresia Diseases 0.000 claims description 4
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 claims description 4
- 208000031513 cyst Diseases 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 201000004541 glycogen storage disease I Diseases 0.000 claims description 4
- 208000033552 hepatic porphyria Diseases 0.000 claims description 4
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 claims description 4
- 201000004515 hepatopulmonary syndrome Diseases 0.000 claims description 4
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims description 4
- 230000007872 intrahepatic cholestasis Effects 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 4
- 201000011374 Alagille syndrome Diseases 0.000 claims description 3
- 241000134916 Amanita Species 0.000 claims description 3
- 208000007257 Budd-Chiari syndrome Diseases 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 241001562190 Galerina Species 0.000 claims description 3
- 241001465236 Gyromitra Species 0.000 claims description 3
- 206010019713 Hepatic vein thrombosis Diseases 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 208000030601 Parasitic Liver disease Diseases 0.000 claims description 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 3
- 229940124347 antiarthritic drug Drugs 0.000 claims description 3
- 235000019504 cigarettes Nutrition 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000019249 food preservative Nutrition 0.000 claims description 3
- 239000005452 food preservative Substances 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 201000009663 hepatic tuberculosis Diseases 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 239000000575 pesticide Substances 0.000 claims description 3
- 239000000779 smoke Substances 0.000 claims description 3
- 201000011296 tyrosinemia Diseases 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 claims description 2
- 208000010362 Protozoan Infections Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002013 dioxins Chemical class 0.000 claims description 2
- 230000007096 poisonous effect Effects 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229950011008 tetrachloroethylene Drugs 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 2
- 108090000854 Oxidoreductases Proteins 0.000 claims 2
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 claims 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- 238000000034 method Methods 0.000 description 55
- 230000002401 inhibitory effect Effects 0.000 description 54
- 230000002000 scavenging effect Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000013270 controlled release Methods 0.000 description 12
- 210000000822 natural killer cell Anatomy 0.000 description 12
- 206010067125 Liver injury Diseases 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 229960004931 histamine dihydrochloride Drugs 0.000 description 9
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 230000005779 cell damage Effects 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010033645 Pancreatitis Diseases 0.000 description 7
- 241001442052 Symphytum Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000037887 cell injury Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 231100000234 hepatic damage Toxicity 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000008818 liver damage Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000007848 Alcoholism Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 206010001584 alcohol abuse Diseases 0.000 description 4
- 208000025746 alcohol use disease Diseases 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 231100000317 environmental toxin Toxicity 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000007863 steatosis Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010033647 Pancreatitis acute Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 201000003229 acute pancreatitis Diseases 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003453 histamine agonist Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012053 oil suspension Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960001660 histamine phosphate Drugs 0.000 description 2
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 235000020888 liquid diet Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 231100000832 liver cell necrosis Toxicity 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 231100000729 Amatoxin Toxicity 0.000 description 1
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 229940123322 Histamine receptor agonist Drugs 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229940123857 NADPH oxidase inhibitor Drugs 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030210 Oesophageal varices haemorrhage Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 108010014709 amatoxin Proteins 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QFXKXRXFBRLLPQ-UHFFFAOYSA-N diphenyleneiodonium Chemical compound C1=CC=C2[I+]C3=CC=CC=C3C2=C1 QFXKXRXFBRLLPQ-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000573 exposure to toxins Toxicity 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- GVYLCNUFSHDAAW-UHFFFAOYSA-N mirex Chemical compound ClC12C(Cl)(Cl)C3(Cl)C4(Cl)C1(Cl)C1(Cl)C2(Cl)C3(Cl)C4(Cl)C1(Cl)Cl GVYLCNUFSHDAAW-UHFFFAOYSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229930002356 pyrrolizidine alkaloid Natural products 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Description
USE OF HISTAMINE TO TREAT LIVER DISEASE
Field of the Invention : [0001] The disclosure below relates to methods for treating and/or preventing hepatic tissue and cell damage caused by reactive oxygen species in mammals. More specifically, the ’ disclosure relates to the prevention and/or reduction and/or reversal of hepatic tissue and cell damage through the administration of histamine and histamine-related compounds.
[0002] Oxidative stress, ie. toxicity inflicted by reactive oxygen species (ROS), is being recognized as a systemic phenomenon in liver disease, whose extent appears to correlate with the severity and stage of disease. The mechanism of action associated with the cellular damage caused by oxidative stress has been implicated in a number of diseases including hepatitis and relates to direct damage of hepatic cells. One author has examined a role for oxidative stress in the development of the hyperdynamic circulation in portal hypertension. Bomzon and Ljubuncic have indicated, however, that it is premature to conclude that oxidative stress per se impacts at least vascular smooth muscle cell function in liver disease. Pharmacol Ther., 89(3):295-308 (2001).
[0003] The theory that oxidative stress may play a role in liver disease may not be surprising as oxidative stress has been proposed to contribute to the state of immunosuppression at the site of malignant tumors and in chronic viral infections. (See U.S. Patent Nos. 5,728,378, 6,000,516, and 6,155,266). Lymphocytes residing within or adjacent to tumors display signs of oxidative damage, including a higher degree of apoptosis and a defective transmembraneous signal transduction. The oxidative stress at the site of tumor growth is presumably conveyed by ROS produced by adjacent phagocytic cells (inonocyte/macrophages (MO) or neutrophilic granulocytes (GR)). Histamine, an inhibitor of ROS production in phagocytes, is currently used as an adjunct to lymphocyte-activating cytokines (IL-2 and IFN-alpha) with the aim to enhance cytokine efficiency.
[0004] Rubin, et al., discusses the use of histamine and other compounds that act as “primers” to treat cancer, including liver cancer. (See U.S. Patent No. 6,303,660). The primer compound is thought to act by increasing the intracellular levels of cyclic adenosine monophosphate (cAMP) in the normal connective tissue cells within solid tumors. Local administration of the primer to an area containing a tumor is thought to result in a lowering of the * interstitial pressure. This reduction in interstitial pressure is also thought to facilitate the uptake of anti-cancer agents. ' [06005] Given the ravaging effects of liver disease and the only partially successful treatment methods available today, there is a constant demand for improved methods of treating liver disease and reducing hepatic cell injury.
[0006] The disclosure relates to methods for treating and/or preventing hepatic tissue and cell damage caused by reactive oxygen species in mammals. More specifically, the disclosure relates to the prevention and/or reduction of hepatic tissue and cell damage through the administration of histamine and histamine agonists. In one embodiment, a method for inhibiting and reducing reactive oxygen species (ROS)-mediated oxidative damage to hepatic cells and tissues of a subject is provided. One aspect of the method comprises the step of administering a compound ' effective to inhibit the production or release of enzymatically produced ROS to a subject suffering from a liver disease caused or exacerbated by ROS-mediated oxidative damage. Although the compositions and methods are applicable to any liver disease, the methods are particularly relevant to the treatment of liver diseases selected from the group consisting of Portal hypertension, Alagille
Syndrome, Alpha-1-Antitrypsin Deficiency, Autoimmune Hepatitis, Biliary Atresia, Chronic
Hepatitis, Cancer of the Liver, Cancer metastatic to the liver, Cirrhosis, Intrahepatic cholestasis,
Hepatic Vein Thrombosis, Hepatic Veno-Occlusive Disease, Hepatolenticular Degeneration,
Hepatomegaly, Hepatopulmonary Syndrome, Hepatorenal Syndrome, Liver Cysts, Liver Abscesses,
Fatty Liver, Galactosemia, Gilbert's Syndrome, Portal Hypertension, Alcoholic Liver Disease (ALD), Parasitic Liver Diseases, Peliosis Hepatis, Erythrohepatic Porphyria, Hepatic Porphyria,
Hepatic Tuberculosis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Reye's Syndrome,
Sarcoidosis, I'yrosinemia, Type I Glycogen Storage Disease, Wilson's Disease, Neonatal Hepatitis,
NonAlchoholic SteatoHepatitis, Hemochromatosis, and Zellweger Syndrome.
[0007] Another embodiment of the disclosure relates to a method for treating a subject suffering from a disease state wherein phagocyte produced, reactive oxygen species (ROS)- mediated oxidative damage can occur. Aspects of the method comprise identifying a subject with a liver disease in which ROS cause ROS-meditated oxidative damage and administering a compound effective to inhibit the production or release of ROS.
[0008] In yet another aspect of the invention, a composition including a compound effective to inhibit the production or release of reactive oxygen species and a hepatotoxic drug is provided. The hepatotoxic drug may be azathioprine, methyldopa, nitrofuratoin, clofibrate, troglizatzone, ibuprofen, allopurinol, indomethacin, leflunomide, acetaminophen, diclofenac, isoniazid, tetracycline, erythromycin, nitrofuratoin, amoxicillin, rifampin, ketoconazole, flucloxacillin, trovafloxacin, sulfonamides, estradiol, iron, glutathione, halothane, isoflurane, captopril, diltiazem, phenytoin, valproic acid, cabamazepine, phenobarbitone, primidone, } trazodone, chlorpromazine, quinidine, procainamide, amiodarone, methotrexate, , cyclophosphamide, corticosteroid, anabolic steroid, glucocorticoids, pyrazinamide, para-amino salicylic acid, ethionamide, trimethoprim-sulfamethoxazole, pentamidine, zidovudine, dideoxyinosine, penicillins, or cephalosporins.
[0009] In another aspect of the invention, herbal preparations are formulated with a compound effective to inhibit the production or release of reactive oxygen species to minimize the hepatotoxic effect of these herbal preparations. Examples of suitable herbs include chapparal . (Larrea tridentata), germander (Teucrium chamaedrys), jin bu huan, ma huang, valerian root (Valeriana officinalis), skullcap (Scutellaria galericulata), mistletoe (Viscum species), Jamaican , bush tea, senna (Cassia angustfolia), comfrey (Symphytum officinale), and kava root extract.
[0010] Advantageously, the compound effective to inhibit the production or release of reactive oxygen species is histamine, histamine receptor agonists, NADPH oxidase inhibitors, serotonin or serotonin agonists. Optionally, the composition further includes an effective amount of a ROS scavenger. The ROS scavenger may be catalase, superoxide dismutase, glutathione peroxidase, or ascorbate peroxidase.
[0011] In yet another aspect of the invention, a method of reducing the hepatotoxicity of a drug by administering to an individual taking a hepatotoxic drug an effective dose of a compound effective to inhibit the production or release of ROSs is provided. The compound effective to inhibit the production or release of ROSs may include histamine, histamine receptor agonists, NADPH oxidase inhibitors, serotonin or serotonin agonists.
[0012] Optionally, the method further includes the step of administering an effective amount of a ROS scavenger. Advantageously, the step of administering said ROS scavenger results in ROS scavenger catalyzed decomposition of ROS. The scavenger can include catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, or vitamin C.
[0013] The hepatotoxic drug may be azathioprine, methyldopa, nitrofuratoin, clofibrate, or troglizatzone. In one aspect of the invention, the hepatotoxic drug is an anti-arthritic drugs such as ibuprofen, allopurinol, indomethacin, leflunomide, acetaminophen, or diclofenac. In another aspect, the hepatotoxic drug is an antibiotic such as isoniazid, tetracycline, erythromycin, nitrofuratoin, amoxicillin, rifampin, ketoconazole, flucloxacillin, trovafloxacin, or sulfonamides.
The hepatotoxic drug may be estradiol, iron, glutathione, halothane, isoflurane, captopril, diltiazem, phenytoin, valproic acid, cabamazepine, phenobarbitone, primidone, trazodone, chlorpromazine; quinidine, procainamide, or amiodarone. The hepatotoxic drug may similarly include a chemotherapeutic agent, corticosteroid, anabolic steroids, or glucocorticoids. . [0014] In yet another aspect of the invention, the hepatotoxic drug is a drug used to treat HIV/AIDS patients such as pyrazinamide, para-amino salicylic acid, ethionamide, ) trimethoprim-sulfamethoxazole, pentamidine, zidovudine, dideoxyinosine, penicillins, and cephalosporins.
[0015] A method of reducing the hepatotoxicity of certain herbal preparations is likewise provided. A compound effective to inhibit the production or release of reactive oxygen species are administered to an individual consuming, for example, chapparal (Larrea tridentata),
germander (Teucrium chamaedrys), jin bu huan, ma huang, valerian root (Valeriana officinalis), skullcap (Scutellaria galericulata), mistletoe (Viscum species), Jamaican bush tea, senna (Cassia angustfolia), comfrey (Symphytum officinale), and/or kava root extract.
[0016] In still another aspect of the present invention, a method of reducing hepatic tissue damage associated with exposure to an environmental or industrial toxin is provided. The ' method includes administering to a subject in need thereof an effective amount of a compound effective to inhibit the production or release of ROS. Advantageously, the compound effective to ' inhibit the production or release of ROS includes histamine, histamine receptor agonists, NADPH oxidase inhibitors, serotonin and serotonin agonists. Optionally, the method may include a further step of administering an effective amount of a ROS scavenger. Preferably, the step of administering the ROS scavenger results in ROS scavenger catalyzed decomposition of ROS. The scavenger may be catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, or vitamin C. The environmental toxin may include a poisonous mushroom from the Amanita, Galerina, or Gyromitra genus. Additionally, the environmental or industrial toxin may include cigarette smoke, pesticides, food additives and/or preservatives, heavy metal, organic solvents, or industrial cleaners, particularly those containing chlorinated solvents.
[0017] The disclosure below relates to compositions and methods for preventing and reducing hepatic cellular and tissue damage caused by reactive oxygen species (ROS).
[0018] The liver plays an essential role in a variety of metabolic functions. Diseases of the liver typically have serious consequences for the person afflicted, ranging from a morbidity to mortality. Examples of liver diseases include: Portal hypertension, Alagille Syndrome, Alpha-1-
Antitrypsin Deficiency, Autoimmune Hepatitis, Biliary Atresia, Chronic Hepatitis, Primary Cancer of the Liver, Cancer metastatic to the liver, Cirrhosis, Intrahepatic cholestasis, Hepatic Vein
Thrombosis, Hepatic Veno-Occlusive Disease, Hepatolenticular Degeneration, Hepatomegaly,
Hepatopulmonary Syndrome, Hepatorenal Syndrome, Liver Cysts, Liver Abscesses, Fatty Liver,
Galactosemia, Gilbert's Syndrome, Portal Hypertension, Alcoholic Liver Disease (ALD), Parasitic
Liver Diseases, Peliosis Hepatis, Erythrohepatic Porphyria, Hepatic Porphyria, Hepatic
Tuberculosis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Reye's Syndrome,
Sarcoidosis, Tyrosinemia, Type I Glycogen Storage Disease, Wilson's Disease, Neonatal Hepatitis,
NonAlchoholic SteatoHepatitis, Hemochromatosis, and Zellweger Syndrome. “Alcoholic Liver i
Disease” (ALD), as used herein, includes without limitation, alcoholic fatty liver, alcoholic i hepatitis, alcoholic liver cirrhosis, and fibrosis.
[0019] Recent work has indicated that these and other liver diseases may be caused or exacerbated by ROS. ROS can have direct effects on various cells within the liver parenchema leading to apoptosis. Another possible mechanism by which these molecules can damage hepatic cells and tissue may be related to the effect ROS have on actuator cells of the immune system. For example, ROS evolved from monocytes and other sources have been shown to effectively suppress the activation and activity of NX cells and T-cells. } [0020] The effects of ROS production are many faceted. ROS are known to cause apoptosis in NK cells. ROS are also known to cause anergy and/or apoptosis in T-cells. The , mechanisms by which ROS cause these effects are not yet fully understood. Nevertheless, some commentators believe that ROS cause cell death by disrupting cellular membranes and by changing the pH of cellular pathways critical for cell survival and also by direct damaging effects on DNA.
[0021] The compounds which reduce the amount of ROS produced and released and methods disclosed below are directed to the reduction and prevention of ROS mediated damage of hepatic cells and tissue. In preferred embodiments, various histamine and histamine-related compounds are used to achieve a beneficial reduction or inhibition of enzymatic ROS production and release or the net concentration thereof. The term "histamine" as used herein incorporates a variety of histamine and histamine related compounds. For example, histamine, the dihydrochloride salt form of histarnine (histamine dihydrochloride), histamine diphosphate, other histamine salts, esters, or prodrugs, and histamine receptor agonists are to be included. Also included within the meaning of the term “histamine” are histamine binding mimics and NADPH oxidase inhibitors.
[0022] The administration of compounds that induce the release of endogenous histamine from a patient's own tissue stores is also included within the scope of the present disclosure. Such compounds include IL-3, retinoids, and allergens. Other ROS production and release inhibitory compounds such as NADPH oxidase inhibitors like diphenyleneiodonium can also be used with the disclosed methods, as can serotonin and SHT-receptor agonists.
[0023] The compositions and methods disclosed herein also encompass the administration of a variety of ROS scavengers. Known scavengers of ROS include the enzymes catalase, superoxide dismutase (SOD), glutathione peroxidase and ascorbate peroxidase.
Additionally, vitamins A, E, and C are known to have scavenger activity. Minerals such as selenium and manganese can also be efficacious in combating ROS-mediated damage. The scope of the methods disclosed herein includes the administration of the compounds listed and those compounds with similar ROS inhibitor activity. The compositions and methods disclosed herein also provide an effective means for preventing and/or inhibiting the release of enzymatically generated . ROS in excessive amounts or at inappropriate times or locations.
[0024] Compounds and methods for treating hepatic disease states that are \ complicated by the detrimental release of ROS within a host or subject are provided. The liver is responsible for many essential functions in the body. Because of these activities, the liver is exposed to a wide variety of insults and is therefore one of the most frequently injured organs in the body. The impairment of these vital functions by hepatic disease can lead to very serious consequences. Liver damage has been linked to a number of sources. Hepatitis, or inflammation of the liver, may be caused by infections with viruses, bacteria, fungi, or protozoa or may result from exposure to toxins such as alcohol, drugs, chemical poisons, or other environmental toxins.
Vascular and metabolic disorders, neoplastic disease, and/or the liver’s involvement in extrahepatic disorders such as autoimmune disease have similarly been linked to damage of hepatic tissue.
Examples of autoimmune diseases wherein liver tissue becomes comprised include lupus erythematosus and rheumatoid arthritis. Additionally, in patients suffering from heart failure, the liver is often damaged from congestion, scarring, and ascites formation. !
[0025] In the case of industrial and environmental toxins, primary disease is caused by the ingestion, injection, or inhalation of a toxic substance which adversely affects the liver. For example, herbicides, such as paraquat, are associated with an increased incidence of liver damage.
Similarly, the ingestion of certain genuses of mushrooms can result in grave damage to hepatic cells and even death. Such mushrooms include the Amanita and the Galerina genuses which contain amatoxin, the substance responsible for hepatic and renal destruction. Hepatic necrosis, similar to that produced by acetaminophen over dosage, is the primary toxic manifestation. Mushrooms from the genus Gyromitra have likewise been associated with hepatotoxicity and hepatorenal syndrome in severe cases. Examples of environmental and industrial toxins which cause damage to hepatic tissue include, without limitation, cigarette smoke, industrial cleaners, diethanoloamine, sodium laurel sulfate, propylene glycol, pesticides such as DDT and mirex, food additives and preservatives, heavy metals, organic solvents such as formaldehyde and bromobenzene, and chlorinated solvents such as dioxins, flurans, TCE, PCE, DCE, tetrachloroethylene, carbon tetrachloride, and vinyl chloride.
[0026] As will be described in greater detail below, liver toxins also include many common drugs, such as acetaminophen, anabolic steroids, chemotherapy drugs, some antibiotics, glucocorticoids, anaesthetics, parasite control drugs, and phenylbutazone. Certain anticonvulsants are associated with hepatopathy such as phenobarbital, primidone, and phentoin. Damage to liver tissue results, at least in part, by the detrimental release of ROS within a host or subject in response to such insults. Accordingly, compositions and methods for treating damage to liver tissue caused by exposure to toxic substances are provided. Specifically, the administration of a ROS production and release inhibiting compound is useful for the reduction in trauma to hepatic cells and tissues following exposure to industrial and/or environmental toxins.
[0027] Numerous medications have been associated with damage to the liver.
Approximately 10% of all cases of hepatitis in young adults and 40% of cases in patients older than ) 50 are caused by medications. As used herein, “hepatotoxic drugs” include any substance or . substances which act upon the liver to cause tissue damage. Examples of hepatotoxic drugs include, without limitation, anti-diabetic and immunosuppressive drugs such as azathioprine, methyldopa, nitrofuratoin, clofibrate, and troglizatzone; anti-arthritic drugs such as ibuprofen, allopurinol, indomethacin, leflunomide, acetaminophen, diclofenac; antibiotics such as isoniazid,
tetracycline, erythromycin, nitrofuratoin, amoxicillin, rifampin, ketoconazole, flucloxacillin, trovafloxacin, and sulfonamides; estradiol; iron; vitamin A; glutathione; certain anesthetics such as halothane and isoflurane; anti-hypertensive drugs including captopril and diltiazem; anti- ] convulsants and anti-depressants such as phenytoin, valproic acid, cabamazepine, phenobarbitone, primidone, and trazodone; anti-psychotics such as chlorpromazine; anti-arrhythmics like quinidine, , procainamide, and amiodarone; chemotherapeutics such as methotrexate and cyclophosphamide; steroids including corticosteroid, anabolic steroids, and glucocorticoids; and drugs commonly used in HIV/AIDS patients such as pyrazinamide, para-amino salicylic acid, ethionamide, trimethoprim- sulfamethoxazole, pentamidine, zidovudine, dideoxyinosine, penicillins, and cephalosporins.
Additionally, herbal preparations such as chapparal (Larrea tridentata); germander (Teucrium chamaedrys); certain Chinese herbs including jin bu huan and ma huang; valerian root (Valeriana officinalis); skullcap (Scutellaria galericulata); mistletoe (Viscum species); herbal teas such as
Jamaican bush tea (pyrrolizidine alkaloids); senna (Cassia angustfolia); comfrey (Symphytum officinale); and kava root extract are known hepatotoxins.
[0028] Compositions and methods for minimizing the hepatotoxicity of certain drugs are provided. With many diseases such as HIV/AIDS, the treatment can seem as onerous as the disease. In the case of HIV infection, the drugs designed to reduce viral loads often compromise liver cells and can result in grave consequences. Accordingly, ROS inhibiting or scavenging compounds can be administered to an individual who is concurrently taking a drug or drugs which cause hepatotoxic side effects to mitigate damage to liver cells caused by the hepatotoxic drug. In one embodiment, an individual taking a hepatotoxic drug is administered an effective amount of a
ROS inhibiting compound or scavenger separately or as a single formulation with the hepatotoxic drug. The ROS inhibiting compound or scavenger and hepatotoxic drug may be given substantially simultaneously or within various time durations of each other. The administration can be by either local or by systemic injection or infusion. Other methods of administration may also be suitable, such as by oral route.
[0029] The administration of an ROS inhibitor or scavenger is likewise useful for ameliorating damage to liver tissue caused or exacerbated by bacterial, fungal, viral, or protozoan infections. Helicobacter and Leptospirosis are just two examples of a species of pathogenic bacteria which invades the liver and causes tissue damage. Blasomycosis, histoplasmosis, and coccidiomycosis are examples of fungal infections which attack liver tissue. Systemic infections, d such as tuberculosis, candidiasis, and toxoplasmosis, often spread to the liver and can cause damage to the liver tissue. Moreover, nearly all blood-born infections will inevitably involve the liver.
[0030] Accordingly, in one aspect of the present invention, compounds and methods for minimizing damage to liver tissue associated with bacterial, fungal, viral, or protozoal infections are provided. ROS production and release inhibiting compounds are administered alone or in combination with an antibiotic. As used herein, the term “antibiotic” includes any antibacterial,
antifungal, or anti-protozoal compound. When administered in combination with antibiotics, the
ROS production and release inhibiting compound of the present invention can be administered separately or as a single formulation with the antibiotic. If administered separately, the ROS production and release inhibiting compound should be given in a temporally proximate manner such that the amelioration of damage to liver tissue is enhanced. In one embodiment, the ROS ) production and release inhibiting compound and antibiotic are given within one week of each other.
In another embodiment, the ROS production and release inhibiting compound and antibiotic are ' given within twenty-four hours of each other. In yet another embodiment, the ROS production and release inhibiting compound and antibiotic are given within one hour of each other. The administration can be by either local or by systemic injection or infusion. Other methods of administration may also be suitable such as oral administration.
[0031] In yet another embodiment, compositions and methods for treating liver diseases secondary to other disease etiologies are provided. Because of the close proximity of the pancreas to the liver and the bile ducts, acute pancreatitis often leads to hepatitis. Similarly, chronic inflammation of the bowel allows portal absorption of toxic intestinal products and bacteria which can compromise the tissue of the liver. Shock, anemia, and congestive heart failure result in severe loss of blood circulation to the liver and lack of oxygen, which can likewise lead to damage to liver tissue. Similarly, while primary cancer of the liver is rare, it is common for cancer to spread to the liver as a secondary metastatic cancer from the colon, lungs, breasts, or other parts of the body.
Therefore, compositions comprising an ROS inhibiting compound or scavenger are useful for treating liver diseases which are secondary to other diseases. In one embodiment, a patient suffering from acute pancreatitis is administered an effective dose of an ROS inhibiting compound or scavenger to prevent damage to hepatic cells. In another embodiment, an individual with metastatic cancer of the liver is administered an effective dose of an ROS inhibiting compound or scavenger with or without chemotherapeutic agents to minimize damage to the liver.
[0032] The administration of the disclosed compounds can be alone or in combination with other compounds effective at treating various hepatic disease states. For example, histamine can be used to treat a patient suffering from nonalchoholic steatohepatitis (NASH). Further, the disclosed methods and compounds can be used with standard NASH treatment regimes, which usually comprise a low fat, low calorie diet along with insulin or medications to lower blood sugar for obese patients. For patients with NASH who are not overweight and not diabetic, a low fat diet is often recommended. Also, as discussed above, individuals presenting with metastatic cancer of ) the liver are administered an effective dose of an ROS inhibiting compound or scavenger along x with standard chemotherapy and/or radiation protocols. In the case of viral infections of the liver, a subject can be administered an anti-viral therapy concurrently with the administration of an ROS inhibiting compound or scavenger to minimize hepatic cell injury. For example, an ROS inhibiting compound or scavenger can be used to treat an individual presenting with Hepatitis C along with standard hepatitis treatment regimes including the administration of ribavirin or pegylated INF-a.
[0033] Similarly, the disclosed methods and compounds are useful for the treatment of . alcoholic liver diseases. Alcohol abuse is a leading cause of morbidity and mortality throughout the world. It is estimated that in the United States as many as 10 % of men and 3 % of women may ' suffer from persistent problems related to the use of alcohol. Alcohol affects many organ systems of the body, but perhaps most notably affected is the liver because almost all ingested alcohol must be metabolized in the liver. Alcohol abuse generally leads to three pathologically distinct liver diseases: fatty liver (steatosis), alcoholic hepatitis, and cirrhosis. Fatty liver is characterized by the accumulation of fat within hepatocytes, the predominant cell type in the liver. Alcohol can also cause acute and chronic hepatitis. Alcoholic hepatitis can lead to liver scarring and cirrhosis, and very frequently occurs in alcoholics who already have cirrhosis of the liver. Finally, liver cirrhosis resulting from alcohol abuse is characterized by the development of widespread nodules in the liver combined with fibrosis and can lead to end-stage liver disease. Alcohol-related cirrhosis is one of the ten leading causes of death in the United States. Some of the complications of cirrhosis are jaundice, ascites, edema, bleeding esophageal varices, blood coagulation abnormalities, coma and death. Thus, in one embodiment, the disclosed methods and compositions are administered to a subject suffering from alcoholic liver disease (ALD). A subject suffering from ALD is identified and administered an effective dose of an ROS inhibiting or scavenging compound.
[0034] The use of the ROS inhibiting or scavenging compounds can be by any of a number of methods well known to those of skill in the art. For oral administration, the ROS inhibiting or scavenging compounds may be incorporated into a tablet, aqueous or oil suspension, dispersible powder or granule, microbead, emulsion, hard or soft capsule, syrup or elixir. The compositions may be prepared according to any method known in the art for the manufacture of pharmaceutically acceptable compositions and such compositions may contain one or more of the following agents: sweeteners, flavoring agents, coloring agents and preservatives. Tablets containing the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients suitable for tablet manufacture are acceptable. “Pharmaceutically acceptable” means that the agent should be acceptable in the sense of being compatible with the other ingredients of the formulation (as well as non-injurious to the individual). Such excipients include inert diluents such . as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as corn starch and alginic acid; binding agents such as . starch, gelatin or acacia; and lubricating agents such as magnesium stearate, stearic acid or talc.
Tablets may be uncoated or may be coated with known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time. For example, a time delay material such as glyceryl monostearate or glyceryl stearate alone or with a wax may be employed.
[0035] In another preferred embodiment, tablets, capsules or microbeads are coated with an enteric coating which prevents dissolution in the acidic environment of the stomach.
Instead, this coating dissolves in the small intestine at a more neutral pH. Such enteric coated compositions are described by Bauer et al., Coated Pharmaceutical Dosage Forms:
Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Raw
Materials, CRC Press, Washington, DC, 1998.
[0036] Formulations for oral use may also be presented as hard gelatin capsules ' wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
[0037] Aqueous suspensions may contain the ROS inhibiting or scavenging compounds of the invention in admixture with excipients for the manufacture of aqueous suspensions. Such excipients include suspending agents, dispersing or wetting agents, one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents such as sucrose or saccharin.
[0038] Oil suspensions may be formulated by suspending the aclive ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspension may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by an added antioxidant such as ascorbic acid. Dispersible powders and granules of the compounds of the invention, suitable for preparation of an aqueous suspension by the addition of water, provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
[0039] Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
[0040] The use of the ROS inhibiting or scavenging compounds can also be accomplished via parenteral delivery through subcutaneous, intravenous, intraperitoneal, or intramuscular injection. The compounds can be administered in an aqueous solution with or without a surfactant such as hydroxypropyl cellulose. Dispersions are also contemplated such as ) those utilizing glycerol, liquid polyethylene glycols, and oils. Injectable preparations can include i sterile aqueous solutions or dispersions and powders that can be diluted or suspended in a sterile environment prior to use. Carriers such as solvents or dispersion media contain water, ethanol polyols, vegetable oils and the like can also be added to the disclosed compounds. Coatings such as : lecithins and surfactants can be used to maintain the proper fluidity of the composition. Isotonic agents such as sugars or sodium chloride can be added, as well as products intended to delay absorption of the active compounds such as aluminum monostearate and gelatin. Sterile injectable solutions are prepared according to methods well known to those of skill in the art and can be } filtered prior to storage and/or use. Sterile powders can be vacuum or freeze dried from a solution or suspension. Sustained or controlled release preparations and formulations can also be used with ’ the disclosed methods. Typically the materials used with the disclosed methods and compositions are pharmaceutically acceptable and substantially non-toxic in the amounts employed.
[0041] The disclosed compounds can also be administered by inhalation. In this administration route, histamine can be dissolved in water or some other pharmaceutically acceptable carrier liquid for inhalation, or provided as a dry powder, and then introduced into a gas or powder that is then inhaled by the patient in an appropriate volume so as to provide that patient with a measured amount of histamine. Examples of the administration of a therapeutic composition via inhalation are described in U.S. Patent Nos. 6,418,926; 6,387,394; 6,298,847; 6,182,655; 6,132,394; and 6,123,936.
[0042] Infusion devices can be used to deliver the disclosed compounds. Suitable devices include syringe pumps, auto injector systems, implantable pumps, implantable devices, and minipumps. Exemplary devices include the Ambulatory Infusion Pump Drive, Model 30, available from Microject Corp., Salt Lake City, Utah, and the Baxa Syringe Infuser, available from Baxa
Corporation, Englewood, Colorado. Any device capable of delivering the disclosed compounds in accordance with the methods disclosed herein can be used.
[0043] Suitable infusion devices preferably have an effective amount of histamine, histamine agonist, histamine salt, histamine prodrug, NADPH-oxidase inhibitor, histamine dihydrochloride, histamine phosphate, serotonin, a SHT agonist, a histamine receptor agonist, histamine receptor binding mimic, or a substance which induces the release of an effective therapeutic amount of endogenous histamine contained therein. The device can be pre-loaded with the desired substance during manufacture, or the device can be filled with the substance just prior to use. Pre-filled infusion pumps and syringe pumps are well known to those of skill in the art. The active substance can be part of a formulation which includes a controlled release carrier, if desired. A controller is used with the device to control the rate of administration and the amount of substance to be administered. The controller can be integral with the device or it can be a separate entity. It can be pre-set during manufacture, or set by the user just prior to use. Such controllers and their use with infusion devices . are well known to those of skill in the art.
[0044] Controlled release vehicles are well known to those of skill in the pharmaceutical . sciences. The technology and products in this art are variably referred to as controlled release, sustained release, prolonged action, depot, repository, delayed action, retarded release and timed release; the words "controlled release" as used herein is intended to incorporate each of the foregoing technologies.
[0045] Numerous controlled release vehicles are known, including biodegradable or bioerodable polymers such as polylactic acid, polyglycolic acid, and regenerated collagen. Known controlled release drug delivery devices include creams, lotions, tablets, capsules, gels, microspheres, liposomes, ocular inserts, minipumps, and other infusion devices such as pumps and syringes. Implantable or injectable polymer matrices, and transdermal formulations, from which ) active ingredients are slowly released are also well known and can be used in the disclosed methods. '
[0046] In one embodiment, the disclosed compounds are administered through a topical delivery system. The controlled release components described above can be used as the means to delivery the disclosed compounds. A suitable topical delivery system comprises the disclosed compounds in concentrations taught herein, a solvent, an emulsifier, a pharmaceutically acceptable carrier material, penetration enhancing compounds, and preservatives. Examples of topically applied compositions include U.S. Patent No. 5,716,610 and 5,804,203. The compositions can further include components adapted to improve the stability or effectiveness of the applied formulation, such as preservatives, antioxidants, skin penetration enhancers and sustained release materials. Examples of such components are described in the foilowing reference works:
Martindale— The Extra Pharmacopoeia (Pharmaceutical Press, London 1993) and Martin (ed.),
Remington's Pharmaceutical Sciences.
[0047] Controlled release preparations can be achieved by the use of polymers to complex or absorb the ROS inhibiting or scavenging compound. The controlled delivery can be exercised by selecting appropriate macromolecule such as polyesters, polyamino acids, polyvinylpyrrolidone, ethylenevinyl acetate, methylcellulose, carboxymethylcellulose, and protamine sulfate, and the concentration of these macromolecule as well as the methods of incorporation are selected in order to control release of active compound.
[0048] Hydrogels, wherein the ROS inhibiting or scavenging compound is dissolved in an aqueous constituent to gradually release over time, can be prepared by copolymerization of hydrophilic mono-olefinic monomers such as ethylene glycol methacrylate. Matrix devices, wherein the ROS inhibiting or scavenging compound is dispersed in a matrix of carrier material, can be used.
The carrier can be porous, non-porous, solid, semi-solid, permeable or impermeable. Alternatively, a device comprising a central reservoir of the ROS inhibiting or scavenging compound surrounded by a rate controlling membrane can be used to control the release of the ROS inhibiting or scavenging compound. Rate controlling membranes include ethylene-vinyl acetate copolymer or butylene ) terephthalate/polytetramethylene ether terephthalate. Use of silicon rubber depots are also . contemplated.
[0049] Controlled release oral formulations are also well known. In one embodiment, the active compound is incorporated into a soluble or erodible matrix, such as a pill or a lozenge. Such formulations are well known in the art. An example of a lozenge used to administer pharmaceutically active compounds is U.S. Patent No. 5,662,920. In another example, the oral formulations can be a liquid used for sublingual administration. An example of pharmaceutical compositions for liquid sublingual administration of the disclosed compounds are taught in U.S. Patent No. 5,284,657. These ) liquid compositions can also be in the form a gel or a paste. Hydrophilic gums, such as hydroxymethylcellulose, are commonly used. A lubricating agent such as magnesium stearate, stearic , acid, or calcium stearate can be used to aid in the tableting process.
[0050] For the purpose of parenteral administration, ROS inhibiting or scavenging compounds can be combined with distilled water, preferably buffered to an appropriate pH and having appropriate (e.g., isotonic) salt concentrations. The compounds of the present invention can also be provided as a liquid or as a powder that is reconstituted before use. They can be provided as prepackaged vials, syringes, or injector systems.
[0051] The disclosed compounds, such as histamine, can also be provided in septum- sealed vials in volumes ranging from about 0.5 to 100 ml for administration to an individual. In a preferred embodiment, the vials contain volumes 0f0.5,1,3,5,6,8, 10, 20, 50 and 100 ml. The vials are preferably sterile. The vials can optionally contain an isotonic carrier medium and/or a preservative. Any desired amount of histamine can be used to give a desired final histamine concentration. In a preferred embodiment, the ROS inhibiting or scavenging compound concentration is between about 0.01 mg/ml and 100 mg/ml. More preferably, the ROS inhibiting or scavenging compound concentration is between about 0.1 and 50 mg/ml. Most preferably, the ROS inhibiting or scavenging compound concentration is between about 1 mg/ml and 10 mg/ml. At the lower end of the volume range, it is preferred that individual doses are administered, while at the higher end it is preferred that multiple doses are administered.
[0052] In a preferred embodiment, transdermal patches, steady state reservoirs sandwiched between an impervious backing and a membrane face, and transdermal formulations, can also be used to deliver ROS inhibiting or scavenging compounds. Transdermal administration systems are well known in the art. Occlusive transdermal patches for the administration of an active agent to the skin or mucosa are described in U.S. Patent Nos. 4,573,996, 4,597,961 and 4,839,174. One type of transdermal patch is a polymer matrix in which the active agent is dissolved in a polymer matrix through which the active ingredient diffuses to the skin. Such transdermal patches are disclosed in U.S.
Patent Nos. 4,839,174, 4,908,213 and 4,943,435. In one embodiment, the steady state reservoir carries . doses of histamine and other ROM production and release inhibitory compounds in doses from about 0.2 to 5 mg per day. , [0053] Present transdermal patch systems are designed to deliver smaller doses over longer periods of time, up to days and weeks. A preferred delivery system for the disclosed compounds would specifically deliver an effective dose of histamine in a range of between about 2 and 60 minutes, depending upon the dose, with a preferred dose being delivered within about 20-30 minutes. These patches allow rapid and controlled delivery of a compound which inhibits or scavenges
ROS. A rate-controlling outer microporous membrane, or micropockets of the disclosed compounds dispersed throughout a silicone polymer matrix, can be used to control the release rate. Such rate- controlling means are described in U.S. Patent No. 5,676,969. In another preferred embodiment, the histamine or other ROM inhibiting or scavenging compound is released from the patch into the skin of the patient in about 20-30 minutes or less. In a preferred embodiment, the compound is released from the patch at a rate of between about 0.025 mg to 0.5 mg per minute for a dose of between about 0.2 mg and 5 mg per patch. '
[0054] These transdermal patches and formulations can be used with or without use of a penetration enhancer such as dimethylsulfoxide (DMSO), combinations of sucrose fatty acid esters with a sulfoxide or phosphoric oxide, or eugenol. The use of electrolytic transdermal patches is also within the scope of the methods disclosed herein. Electrolytic transdermal patches are described in
U.S. Patent Nos. 5,474,527, 5,336,168, and 5,328,454.
[0055] In another embodiment transmucosal patches can be used to administer the disclosed compounds. An example of such a patch is found in U.S. Patent No. 5,122,127. The described patch comprises a housing capable of enclosing a quantity of therapeutic agent where the housing is capable of adhering to mucosal tissues, for example, in the mouth. A drug surface area of the device is present for contacting the mucosal tissues of the host. The device is designed to deliver the drug in proportion to the size of the drug/mucosa interface. Accordingly, drug delivery rates can be adjusted by altering the size of the contact area. 10056] The housing is preferably constructed of a material which is nontoxic, chemically stable, and non-reactive with the disclosed compounds. Possible construction materials include: polyethylene, polyolefins, polyamides, polycarbonates, vinyl polymers, and other similar materials known in the art. The housing can contain means for maintaining the housing positioned against the mucosal membrane. The housing can contain a steady state reservoir positioned to be in fluid contact with mucosal tissue.
[0057] Steady state reservoirs for use with the disclosed compounds delivery a suitable dose of those compounds over a predetermined period of time. Compositions and methods of manufacturing compositions capable of absorption through the mucosal tissues are taught in U.S.
Patent No. 5,288,497. One of skill in the art could readily include the disclosed compounds and related compositions.
[0058] The steady state reservoirs for use with the disclosed compounds are composed of compounds known in the art to control the rate of drug release. In one embodiment, the transmucosal ) patch delivers a dose of a ROS inhibiting or scavenging compound over a period of time from about 2 to 60 minutes. The steady state reservoir contained within the housing carries doses of histamine and other ROS production and release inhibitory or scavenging compounds in doses from about 0.2 to 100 mg per patch. Transdermal patches that can be worn for several days and that release the disclosed compounds over that period of time are also contemplated. The reservoirs can also contain permeation or penetration enhancers, as discussed above, to improve the permeability of the disclosed compounds across the mucosal tissue.
[0059] Another method to control the release of the disclosed compounds is to incorporate the ROS inhibiting or scavenging compound into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly lactic acid, or ethylene vinylacetate copolymers.
R [0060] Alternatively, instead of incorporating the ROS inhibiting or scavenging compounds into these polymeric particles, the disclosed compounds are entrapped in microcapsules prepared, for example, by coacervation techniques, or by interfacial polymerization, for example hydroxymethylcellulose or gelatin-microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules, or in macroemulsions. Such technology is well known to those of ordinary skill in pharmaceutical sciences.
[0061] Preferably, the compounds that inhibit or scavenging ROS are inj ected, infused, or released into the patient at a rate of from about 0.025 to 1.0 mg/min. A rate of about 0.1 mg/min is preferred. The disclosed compounds are preferably administered over a period of time ranging from about 1, 3 or 5 minutes to about 30 minutes, with an upper limit of about 20 minutes being preferred, such that the total daily adult dose of ROS inhibiting or scavenging compound ranges from between about 0.4 to about 100.0 mg, with about 0.5 to about 20.0 mg being preferred. Compounds of the present invention, such as histamine, administered over longer periods of time, i.e., longer than about minutes, have been found to result in decreased or lack of efficacy, while rapid administration over less than 1 - 3 minutes can cause more pronounced and serious side effects, which include anaphylaxis, heart failure, bronchospasm, pronounced flushing, discomfort, increased heart rate and respiratory rate, hypotension, and severe headache.
[0062] In another embodiment, an ROS inhibiting compound at approximately 0.2 to 2.0 mg or 3-200 pg/kg, in a pharmaceutically acceptable form can be administered. ROS scavenging compounds can also be administered in combination with the ROS production and release inhibitory compounds described above. When the ROS inhibiting or scavenging compound is administered orally, the composition can be formulated as a tablet comprising between 10 mg to 2 grams of active ingredient. A tablet can include 10, 20, 50, 100, 200, 500, 1,000, or 2,000 milligrams of ROS inhibiting or scavenging compound. Preferably, the amount of ROS inhibiting or scavenging compound in a tablet is 100 mg. In some embodiments, the composition includes histamine protectors ‘ such as diamine oxidase inhibitors, monoamine oxidase inhibitors and n-methy] transferases.
[0063] The treatment can also include periodically boosting patient blood ROS inhibiting or scavenging compound levels by administering 0.2 to 2.0 mg or 3-200 ng/kg of the disclosed compounds injected or ingested 1, 2, or more times per day over a period of one to two weeks at regular intervals, such as daily, bi-weekly, or weekly in order to establish blood levels of ROS inhibiting or scavenging compound at a beneficial concentration such that ROS production and release is inhibited. The treatment is continued until the causes of the patient’s underlying disease state 1s controlled or eliminated.
[0064] Administration of each dose of ROS inhibiting or scavenging compound can occur from once a day to up to about four times a day, with twice a day being preferred.
Administration can be subcutaneous, intravenous, intramuscular, intraocular, oral, transdermal, intranasal, or rectal and can utilize direct hypodermic or other injection or infusion means, or can be mediated by a controlled release mechanism of the type disclosed above. Any controlled release ' vehicle or infusion device capable of administering a therapeutically effective amount of the disclosed compounds over a period of time ranging from about 1 to about 90 minutes can be used. In a preferred embodiment, intranasal delivery is accomplished by using 2 solution of ROS inhibiting or scavenging compound in an atomizer or nebulizer to produce a fine mist which is introduced into the nostrils. For rectal delivery, ROS inhibiting or scavenging compound is formulated into a suppository using methods well known in the art.
[0065] Compounds that scavenge ROS can be administered in an amount of from about 0.1 to about 20 mg/day; more preferably, the amount is from about 0.5 to about 8 mg/day; more preferably, the amount is from about 0.5 to about 8 mg/day; and even more preferably, the amount is from about 1 to about 5 mg/day. Nevertheless, in each case, the dose depends on the activity of the administered compound. The foregoing doses are appropriate for the enzymes listed above that include catalase, superoxide dismutase (SOD), glutathione peroxidase and ascorbate peroxidase.
Appropriate doses for any particular host can be readily determined by empirical techniques well known to those of ordinary skill in the art.
[0066] Non-enzymatic ROS scavengers can be administered in amounts empirically determined by one of ordinary skill in the art. For example, vitamins A and E can be administered in doses from about 1 to 5000 IU per day. Vitamin C can be administered in doses from about 1 pg to 10 gm per day. Minerals such as selenium and manganese can be administered in amounts from about 1 picogram to 1 milligram per day. These compounds can also be administered as a protective or preventive treatment for ROS mediated disease states.
[0067] In addition to histamine, histamine dihydrochloride, histamine phosphate, other histamine salts, esters, congeners, prodrugs, and H, receptor agonists, the use of serotonin, SHT agonists, and compounds which induce release of histamine from the patient's own tissues is also included within the disclosed methods. Retinoic acid, other retinoids such as 9-cis-retinoic acid and all-trans-retinoic acid, IL-3 and ingestible allergens are compounds that are known to induce the release of endogenous histamine. These compounds can be administered to the patient by oral, intravenous, intramuscular, subcutaneous, and other approved routes. The rate of administration should result in a release of endogenous histamine resulting in a blood plasma level of histamine of about 20 nmol/dl.
[0068] Administration of each dose of a compound which induces histamine release can occur from once per day to up to about four times a day, with twice per day being preferred.
Administration can be subcutaneous, intravenous, intramuscular, intraocular, oral, or transdermal, and can incorporate a controlled release mechanism of the type disclosed above. Any controlled release vehicle capable of administering a therapeutically effective amount of a compound which induces histamine release over a period of time ranging from about one to about thirty minutes can be used.
Additionally, the compounds, compositions, and formulations of the present invention can be , administered quantum sufficiat.
[0069] The following examples teach various methods for treating hepatic disease with the disclosed ROS production and release inhibiting compounds. These examples are illustrative only and are not intended to limit the scope of the claims. The treatment methods described below can be optimized using empirical techniques well known to those of ordinary skill in the art.
Moreover, artisans of ordinary skill would be able to use the teachings described in the following examples to practice the full scope of the claims. Although it is stated in the examples that the administration of an ROS inhibiting compound or scavenger may be given in a single dose, it is obvious that the compounds can be distributed over longer periods of time. Moreover, the daily dose can be administered as a single dose or it can be divided into several doses.
Example 1
Analysis of the effect of histamine dihydrochloride on the protection against early alcohol-induced liver injury in a rat model
[0070] Liver disease leading to hepatitis or inflammation of the liver may be caused by a variety of factors that include infectious agents and toxins. The two most common causes are viral infection and chronic alcohol abuse and in both cases the disease manifests in a similar fashion. The following data strongly supports the hypothesis that free radicals generated from
NADPH oxidase in hepatic Kupffer cells and infiltrating leukocytes play a predominant role in the pathogenesis of early alcohol-induced hepatitis. In this study, we investigated the effect of histamine treatment of early alcohol induced liver injury in a rat model.
Materials and Methods
[0071] Animals and Treatments. Female Wistar rats weighing between 200 and 275 g were fed ad libitum continuously for up to 4 weeks a liquid diet (Dyets, Bethlehem, PA #710034) in . which 35% of the calories were from com oil, 23% were from protein, 5% were from vitamins and minerals, 11% were from maltose-dextrin, and 36% were from ethanol. An isocaloric maltose- dextrin diet (Dyets, #710270) was used for control. Rats were given a single dose of ethanol (5 g/kg body weight intragastrically) using an 18-gauge oral biomedical device (Popper & Sons, Inc.,
New Hyde Park, NY) diluted in PBS (pH 7.2; GIBCO Laboratories Life Technologies Inc., Grand
Island, NY) every 24 hours. Control animals were gavaged with PBS alone. Either histamine dihydrochloride (0.5 mg/kg or 5.0 mg/kg; Sigma Chemical Co., St. Louis, MO) or vehicle (PBS, pH
7.4; GIBCO Laboratories Life Technologies Inc., Grand Island, NY) was administered by subcutaneous injection twice daily for 4 weeks. Body weights of each rat were measured daily.
Rats were housed in a pathogen-free facility and the institutional animal care and use committee approved the surgical procedures used in this study.
[0072] Blood Collection and Enzymatic assays. Blood was collected by cardiac puncture at necropsy after 2 and 4 wk of ethanol treatment and centrifuged. Serum was stored at — °C until it was assayed for alanine aminotransferase (ALT) and aspartate aminotransferase ' (AST) by Sigma diagnostic kits (Sigma Chemical Co., St. Louis, MO).
[0073] Pathological Evaluation. After 2 and 4 weeks of ethanol treatment, livers were formalin fixed, embedded in paraffin, and stained with hematoxylin and eosin to assess steatosis, inflammation, and necrosis. Liver pathology was scored in a blinded manner by an outside expert as follows: 1. Degree of steatosis, score 0-4 (based on % of hepatocytes containing lipid) 0 none 1 minimal (0-24%) 2 mild (25-49%) 3 moderate (50-74%) 4 severe (>= 75%) 2. Degree of inflammatory cell infiltration, score 0-4 0 none, 1 minimal, 2 mild, 3 moderate, 4 severe 3 Degree of degeneration and necrosis, score 0-4 0 none 1 hepatocellular degeneration with no necrosis 2 minimal to mild hepatocellular necrosis (with or without accompanying degeneration) 3 moderate hepatocellular necrosis (with or without accompanying degeneration) 4 severe necrosis (with or without accompanying degeneration)
The points for each grade of histological evaluation were compiled into a total score for each liver.
Results
[0074] The results of the study on the effects of histamine dihydrochloride on the protection against early alcohol induced liver injury in a rat model are summarized below in
Table 1.
~ q
Table 1: Histologic Findings in Liver, Mean Group Severity Scores
En [oe [
Overall Score Control Ethanol Histamine Histamine ‘ Weekd | 263 | 386 | 317 [| 257
[0075] Severity scores for each finding in each group were summed and then divided by the number of animals evaluated per group. The groups were assigned scores as follows: None = 0; Minimal = 3; Mild = 6; Moderate = 9; Severe = 12. Using this method, the trend between groups is demonstrated. A score for an untreated rat on normal food would be 1.00.
[0076] Animals fed a high-fat liquid diet and ethanol developed a typical histology in the liver of alcoholic liver injury, including steatosis, inflammation, necrosis and increased numbers of infiltrating leukocytes mainly neutrophiles and mononuclear cells. Serum levels of alanine and aspartate transaminase (ALT/AST) were elevated approximately two to four-fold in the ethanol treated animals. .
[0077] Animals treated with histamine (0.5 mg/kg or 5 mg/kg) administered twice daily by subcutaneous injection blunted liver injury in a dose dependent manner with the highest dose being most effective. This was assessed by normalization of pathology scores and serum transaminase levels. In addition, livers excised from histamine treated animals were comparative in appearance to livers from the non-ethanol treated group. The livers from ethanol treated animals were generally more pale and with greater accentuated lobular patterns.
[0078] Histamine treated animals had normal liver appearance and tolerated ethanol dosing easier. Initially, all the animals receiving ethanol lost body weight compared to the animals on the control diet. However, both histamine treated groups recovered their body weights more quickly than in the ethanol alone treated group. In addition, these groups had similar weights to the non-ethanol treated control group by the end of the study.
Conclusions
[0079] Preliminary results illustrated a trend for somewhat normal ALT activity in the control and histamine treated groups, with the ethanol control group showing a 2 — 3 fold increase in ALT activity. These results show that histamine significantly lessens the damage in the liver v caused by chronic ethanol administration while on a high fat diet. Moreover, the results of this study suggest that histamine and histamine receptor agonists protect early alcohol-induced liver injury in rats.
Example 2
[0080] This example illustrates the effect of histamine on the lymphocytes isolated from human liver. Three types of human lymphocytes, CD3+ T-cells, CD3-/56+ NK-cells and
CD3+/56+ NK/T-cells were studied regarding their roles in oxidatively induced apoptosis in vitro.
All three cell types became apoptotic after incubation with autologous monocytes (MO) or granulocytes (GR) or after treatment with hydrogen peroxide, a reactive species of oxygen. Thus, at * a lymphocyte to MO ratio of 1:1, 35£5% of T-cells, 55+5% of NK-cells, and 76+7% of NK/T-cells became apoptotic. Corresponding frequencies of apoptosis at a lymphocyte to GR ratio of 1:1 were 21+4% (T-cells), 307% (NK-cells), and 66+8% (NK/T-cells). All data are the mean + s.e.m. (n=15-30 blood donors). Apoptosis in all cell types was significantly prevented by histamine (p<0.001). The higher sensitivity to oxidatively induced apoptosis in NK/T cells and NK-cells was confirmed in experiments in which apoptosis was induced by exogenous hydrogen peroxide; at 25 uM of hydrogen peroxide, 35+5% of T-cells, 65+7% of NK-cells, and 78+7% of NK/T-cells (n=8) became apoptotic. We conclude that liver-type lymphocytes, in particular NK/T-cells, are unusually sensitive to oxidative stress. Thus, anti-oxidative agents such as histamine may be more etfective in liver neoplasia or chronic infection as the result of a higher sensitivity to oxidatively induced apoptosis in liver-infiltrating lymphocytes.
Example 3
Co-administration of histamine and hepatotoxic drug as single formulation 10081] Drug-induced liver disease represents an important challenge for health care providers, the pharmaceutical industry, and regulatory bodies. Drug hepatotoxicity is the single leading cause of acute liver failure in a survey of major medical centers in the U.S. Kaplowitz, N.,
Hepatology 33(1): 308-310 (2001).
[0082] The majority of adverse drug events are acute and present as cytotoxic- hepatitis-like illness or cholestatic disease. Jd. Other reactions to hepatotoxic drugs include chronic hepatitis, vanishing duct disease, fatty liver, non-alcoholic steatohepatitis, fibrosis, cirrhosis, granulomatous disease, veno-occlusive disease, peliosis hepatis, and benign and malignant neoplasia. Damage to the liver can occur due to the dose of drug consumed, apparent hypersensitivity reactions, or metabolic idiosyncratic reactions.
[0083] Without being limited to a particular theory, it is believed that trauma to B hepatic cells in response to insults by hepatotoxic drugs may be caused or exacerbated by ROS. As discussed above, ROS can have direct effects on various cells within the liver parenchema leading to apoptosis. Another possible mechanism by which these molecules can damage hepatic cells and tissue may be related to the effect ROS have on actuator cells of the immune system. ROS production and release inhibiting compounds reduce and/or prevent the ROS mediated damage of hepatic cells and tissue caused by exposure to hepatotoxic drugs.
[0084] An individual presenting with tuberculosis is prescribed an oral tablet ] comprising isoniazid and an effective dose of histamine for a period of six to twelve months.
During the treatment period, the patient is monitored by a physician and lab tests to check the status . of the patient’s liver in response to the medication are performed. Laboratory results confirm no damage to the patients liver in the patient taking a composition comprising both isoniazid and an effective dose of histamine as compared to patients taking isoniazid alone, which may cause severe and sometimes fatal liver damage.
Example 4
[0085] An epileptic taking phenytoin three times a day to control seizures is supplemented with a daily oral dose of 10 mg of histamine dihydrochloride. Prior to supplementation with histamine dihydrochloride, the epileptic experiences liver damage as a consequence of taking phenytoin as confirmed by liver biopsy. After supplementation with histamine dihydrochloride, further damage to the tissue of the liver is prevented.
Example 5
Herbal preparation comprising a ROS scavenger
[0086] Herbal remedies, vitamins and herbal supplements have been gaining in popularity over the past decade. Comfrey has been used for centuries with success in wound healing and promoting bone health. Comfrey has also been hailed as a powerful remedy for coughs, catarrh, ulcerated bowels and stomach.
[0087] The common herb comfrey can be administered as a poulitice or tea drink to as an expectorant, demulcent, and/or tonic. However, consumption of comfrey has been linked to liver damage. In order to minimize the hepatotoxic effect of comfrey, an individual consuming comfrey as an herbal remedy is supplemented with 8 mg/day of catalase. No hepatic injury is observed.
Example 6
Prevention of hepatic tissue damage secondary to pancreatitis
[0088] The invention contemplates the treatment of pancreatitis and other v inflammatory diseases in addition to hepatitis. Inflammation caused by TNF-a and interleukins as part of an individual’s immune response can also drive damage to tissue. Histamine and histamine- related compounds block these pro-inflammatory cytokines, thereby ameliorating some of the damage to cells caused by inflammation. For a detailed discussion of the role of histamine and histamine-related compounds on mitigating damage to tissue caused by pro-inflammatory cytokines, see U.S. Patent No. 6,242,473 and U.S. Patent Application Ser. No. 09/139,281.
[0089] A patient presenting with acute pancreatitis is identified. The patient is administered 100 pg/kg histamine diphosphate per day over a period of one to two weeks. A liver biopsy is performed upon resolution of the pancreatitis. The administration of histamine diphosphate prevents darnage to hepatic tissue and lowers the incidence of infection associated with pancreatitis.
Example 7
Treatment of bacterial infection of the liver )
[0090] An individual presenting with a bacterial infection caused by a species of
Helicobacter is identified. The individual is administered antibiotics in concert with an effective dose of a histamine prodrug. The period of infection is reduced and the trauma to hepatic cells is minimized.
[0091] The foregoing description details certain embodiments of the invention. It will be appreciated, however, that no matter how detailed the foregoing appears in text, the invention can be practiced in many ways. As is also stated above, it should be noted that the use of particular terminology when describing certain features or aspects of the invention should not be taken to imply that the terminology is being re-defined herein to be restricted to including any specific characteristics of the features or aspects of the invention with which that terminology is associated.
The scope of the invention should therefore be construed in accordance with the appended claims and any equivalents thereof.
Claims (43)
1. Use of a composition comprising a compound effective to reduce the amount of reactive oxygen species (ROS) in an individual for the manufacture of a medicament for the treatment of ROS-mediated oxidative damage to hepatic cells and tissues.
2, The use of Claim 1, wherein said compound is selected from the group consisting of a : compound effective to inhibit the production or release of enzymatically produced ROS, an ROS scavenger, and combinations thereof.
3, The use of Claim 2, wherein the ROS is released constitutively.
4. The use of Claim 1, wherein said damage is associated with a liver disease selected from the group consisting of Portal hypertension, Alagille Syndrome, Alpha-1-Antitrypsin Deficiency, Autoimmune Hepatitis, Biliary Atresia, Chronic Hepatitis, Cancer of the Liver, Cancer metastatic to the liver, Cirrhosis, Intrahepatic cholestasis, Hepatic Vein Thrombosis, Hepatic Veno-Occlusive Disease, Hepatolenticular Degeneration, Hepatomegaly, Hepatopulmonary Syndrome, Hepatorenal Syndrome, Liver Cysts, Liver Abscesses, Fatty Liver, Galactosemia, Gilbert's Syndrome, Portal Hypertension, Alcoholic Liver Disease (ALD), Parasitic Liver Diseases, Peliosis Hepatis, Erythrohepatic Porphyria, Hepatic Porphyria, Hepatic Tuberculosis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Reye's Syndrome, Sarcoidosis, Tyrosinemia, Type I Glycogen Storage Disease, Wilson's Disease, Neonatal Hepatitis, NonAlchoholic SteatoHepatitis, Hemochromatosis, and Zellweger Syndrome.
5. The use of Claim 2, wherein the compound effective to inhibit the production or release of enzymatically produced ROS is selected from the group consisting of histamine, histamine receptor agonists, NADPH oxidase inhibitors, serotonin and serotonin agonists.
6. The use of Claim 2, wherein the scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, and vitamin C.
7. The use of Claim 1, wherein said damage is associated with a liver disease selected from the group consisting of bacterial infection, fungal infection, and protozoan infection.
8. The use of Claim 7, wherein said composition further comprises an antibiotic.
9. The use of Claim 8, wherein said antibiotic is administered substantially simultaneously with said compound effective to inhibit the production or release of enzymatically produced ROS. .
10. The use of Claim 8, wherein said antibiotic is administered within 24 hours of said compound effective to inhibit the production or release of enzymatically produced ROS.
11. Use of a composition comprising a compound effective to reduce the amount of ROS in an individual for the manufacture of a medicament for treating a subject suffering from liver disease.
12. The use of Claim 11, wherein said wherein said liver disease is selected from the group consisting of Portal hypertension, Alagille Syndrome, Alpha-1-Antitrypsin Deficiency, Autoimmune Hepatitis, Biliary Atresia, Chronic Hepatitis, Cancer of the Liver, Cancer metastatic to the liver, Cirrhosis, Intrahepatic cholestasis, Hepatic Vein Thrombosis, Hepatic Veno-Occlusive Disease, Hepatolenticular Degeneration, Hepatomegaly, Hepatopulmonary Syndrome, Hepatorenal Syndrome, Liver Cysts, Liver Abscesses, Fatty Liver, Galactosemia, Gilbert's Syndrome, Portal Hypertension, Alcoholic Liver Disease (ALD), Parasitic Liver Diseases, Peliosis Hepatis, Erythrohepatic Porphyria, Hepatic Porphyria, Hepatic Tuberculosis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Reye's Syndrome, Sarcoidosis, Tyrosinemia, Type I Glycogen Storage Disease, Wilson's Disease, Neonatal Hepatitis, NonAlchoholic SteatoHepatitis, ' Hemochromatosis, and Zellweger Syndrome.
13. The use of Claim 11, wherein said compound effective to reduce the amount of ROS in an individual is selected from the group consisting of a compound effective to inhibit the production or release of ROS, a ROS scavenger, and combinations thereof.
14. The use of Claim 13, wherein said compound effective to inhibit the production or release of ROS is selected from the group consisting of histamine, histamine receptor agonists, serotonin, serotonin agonists, and NADPH oxidase inhibitors.
15. The use of Claim 13, wherein said scavenger is selected from the group consisting of catalase, superoxide dismutase, glutathione peroxidase, and ascorbate peroxidase.
16. A composition comprising a compound effective to reduce the amount of ROS in an individual and a hepatotoxic drug.
17. The composition of Claim 16, wherein said hepatotoxic drug is selected from the group consisting of azathioprine, methyldopa, nitrofuratoin, clofibrate, troglizatzone, ibuprofen, allopurinol, indomethacin, leflunomide, acetaminophen, diclofenac, isoniazid, tetracycline, erythromycin, nitrofuratoin, amoxicillin, rifampin, ketoconazole, flucloxacillin, trovafloxacin, sulfonamides, estradiol, iron, glutathione, halothane, isoflurane, captopril, diltiazem, phenytoin, valproic acid, cabamazepine, phenobarbitone, primidone, trazodone, chlorpromazine, quinidine, procainamide, amiodarone, methotrexate, cyclophosphamide, corticosteroid, anabolic steroid, glucocorticoids, pyrazinamide, para-amino salicylic acid, ethionamide, trimethoprim- sulfamethoxazole, pentamidine, zidovudine, dideoxyinosine, penicillins, and cephalosporins.
18. The composition of Claim 16, wherein said hepatotoxic drug is a herbal preparation selected from the group consisting of chapparal (Larrea tridentata); germander (Teucrium chamaedrys); jin bu huan, ma huang; valerian root (Valeriana officinalis); skullcap (Scutellaria galericulatay; mistletoe (Viscum species); Jamaican bush tea; senna (Cassia angustfolia); comfrey (Symphytum officinale); and kava root extract. ’
19. The composition of Claim 16, wherein said compound is selected from the group consisting of a compound effective to inhibit the production or release of reactive oxygen species, a ROS scavenger, and combinations thereof.
20. The composition of Claim 19, wherein said compound effective to inhibit the production or release of reactive oxygen species is selected from the group consisting of histamine, histamine receptor agonists, NADPH oxidase inhibitors, serotonin and serotonin agonists.
.
21. The composition of Claim 19, wherein said ROS scavenger is selected from the group consisting of catalase, superoxide dismutase, glutathione peroxidase, and ascorbate peroxidase. )
22. Use of a composition comprising an effective dose of a compound effective to reduce the amount of ROS in an individual for the manufacture of a medicament for reducing the hepatotoxicity of a drug.
23. The use of Claim 22, wherein said compound is selected from the group consisting of a compound effective to inhibit the production and release of ROS, an ROS scavenger, and combinations thereof.
24. The use of Claim 23, wherein said compound effective to inhibit the production or release of ROS is selected from the group consisting of histamine, histamine receptor agonists, NADPH : oxidase inhibitors, serotonin and serotonin agonists.
25. The use of Claim 23, wherein the scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, and vitamin C.
26. The use of Claim 22, wherein said hepatotoxic drug is selected from the group consisting of azathioprine, methyldopa, nitrofuratoin, clofibrate, and troglizatzone.
27. The use of Claim 22, wherein said hepatotoxic drug is an anti-arthritic drugs selected from the group consisting of ibuprofen, allopurinol, indomethacin, leflunomide, acetaminophen, and diclofenac.
28. The use of Claim 22, wherein said hepatotoxic drug is an antibiotic selected from the group consisting of isoniazid, tetracycline, erythromycin, nitrofuratoin, amoxicillin, rifampin, ketoconazole, flucloxacillin, trovafloxacin, and sulfonamides.
29. The use of Claim 22, wherein said hepatotoxic drug is selected from the group consisting of estradiol, iron, and glutathione.
30. The use of Claim 22, wherein said hepatotoxic drug is selected from the group consisting of halothane and isoflurane.
31. The use of Claim 22, wherein said hepatotoxic drug is selected from the group consisting of “ captopril, diltiazem, phenytoin, valproic acid, cabamazepine, phenobarbitone, primidone, trazodone, chlorpromazine; quinidine, procainamide, and amiodarone. ,
32. The use of Claim 22, wherein said hepatotoxic drug is a chemotherapeutic agent.
33. The use of Claim 22, wherein said hepatotoxic drug is selected from the group consisting of corticosteroid, anabolic steroids, and glucocorticoids.
34. The use of Claim 22, wherein said hepatotoxic drug is used to treat HIV/AIDS patients.
35. The use of Claim 34, wherein said drug is selected from the group consisting of pyrazinamide, para-amino salicylic acid, ethionamide, trimethoprim-sulfamethoxazole, pentamidine, zidovudine, dideoxyinosine, penicillins, and cephalosporins.
36. The use of Claim 22, wherein said drug is a herbal preparation selected from the group consisting of chapparal (Larrea tridentata); germander (Teucrium chamaedrys); jin bu huan; ma ’ huang; valerian root (Valeriana officinalis); skullcap (Scutellaria galericulata); mistletoe (Viscum species); Jamaican bush tea; senna (Cassia angustfolia); comfrey (Symphytuin officinale); and kava root extract.
37. Use of a composition comprising an effective dose of a compound effective to reduce the amount of ROS in an individual for the manufacture of a medicament for reducing hepatic tissue damage associated with exposure to an environmental or industrial toxin.
38. The use of Claim 37, wherein said compound is selected from the group consisting of a compound effective to inhibit the production or release of ROS, a ROS scavenger, and combinations thereof.
39. The use of Claim 38, wherein said compound effective to inhibit the production or release of ROS is selected from the group consisting of histamine, histamine receptor agonists, NADPII oxidase inhibitors, serotonin and serotonin agonists.
40. The use of Claim 38, wherein the scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, and vitamin C.
41. The use of Claim 37, wherein said toxin is a genus of poisonous mushroom selected from the group consisting of Amanita, Galerina, and Gyromitra.
42. The use of Claim 37, wherein said toxin is selected from the group consisting of cigarette smoke, diethanoloamine, sodium laurel sulfate, propylene glycol, pesticides, food additives, food preservatives, heavy metals, formaldehyde, bromobenzene, and a chlorinated solvent.
43. The use of Claim 42, wherein said chlorinated solvent is selected from the group consisting of dioxins, flurans, TCE, PCE, DCE, tetrachloroethylene, carbon tetrachloride, and vinyl chloride.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34362801P | 2001-10-19 | 2001-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200402530B true ZA200402530B (en) | 2005-01-04 |
Family
ID=34589944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200402530A ZA200402530B (en) | 2001-10-19 | 2004-03-31 | Use of histamine to treat liver disease. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200402530B (en) |
-
2004
- 2004-03-31 ZA ZA200402530A patent/ZA200402530B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030091553A1 (en) | Use of histamine to treat liver disease | |
Gillessen et al. | Silymarin as supportive treatment in liver diseases: A narrative review | |
AU768526B2 (en) | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage | |
US20060002913A1 (en) | Use of histamine and related compounds to treat disorders affecting muscle function | |
KR20050089857A (en) | Inhibitor for liver cancer onset and progress | |
Poormoosavi et al. | Effect of cimetidine on gentamicin-losartan induced-nephrotoxicity in rats | |
US20050171192A1 (en) | Use of histamine to treat bone disease | |
AU2004264255A1 (en) | Method of treating viral infections | |
ZA200402530B (en) | Use of histamine to treat liver disease. | |
AU2002334990A1 (en) | Use of histamine to treat liver disease | |
Wagha et al. | Investigation of hepatoprotective and antioxidant activity of tridax Procumbens Linn.(Asteraceae) extract against rifampicin induced hepatotoxicity in male albino rats | |
EP1263435B1 (en) | Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis | |
Abdel-Rahman et al. | Silymarin ameliorates cisplatin-induced hepatotoxicity in male rabbits | |
Chávez et al. | Are N-Acetylcysteine and Resveratrol Effective Treatments for Liver Disease? | |
US20120039844A1 (en) | Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation | |
AU2004201142B2 (en) | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage | |
Elrahman | The possible protective role of N-acetyl cysteine against tamoxifen-induced hepatotoxicity in the adult female albino rats: Biochemical and Histological study | |
KR970005328B1 (en) | Medical compositions for treating hepatic disease and improving hepatic function | |
Danilenko et al. | Immunomodulating properties of the antimicrobial preparation composed of incapsulated rifampicin and interferon inducer | |
MXPA06001695A (en) | Method of treating viral infections | |
KR20060094875A (en) | Pharmaceutical composition comprising coenzyme q10 for alleviating alcohol intoxication after drinking, method for administering the same |